Clinical trial · Observational
Skin Reactions Related to Thoracic Implantable Chamber Dressings
NCT07158879CI-TRIAL-00094719KPAREACrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, multicenter cohort of 500 patients newly treated with systemic chemotherapy with CCI. The main objective of this study is to measure the incidence of skin reactions related to thoracic implantable chamber dressings.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Diseases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Thoracic catheter port / 1st line chemotherapy
- description
- patients treated with chemotherapy (first-line only) using a thoracic implantable catheter chamber
Primary outcomes (1)
- measure
- Measuring the incidence of skin reactions associated with thoracic implantable chamber dressings
- timeFrame
- through study completion, an average of 18 months
- description
- Appearance of itching and/or erythema (defined as diffuse or localized congestive redness of the skin) at the dressing site
Secondary outcomes (8)
- measure
- Identify risk factors for skin reactions to dressings
- timeFrame
- through study completion, an average of 18 months
- description
- correlation between the onset of skin reactions and the treatments administered
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over 18 years of age * New chemotherapy patients (1st line of treatment only) * Thoracic PAC Exclusion Criteria: * PICC Line and femoral PAC; * Patients undergoing treatment with bi-specific antibodies (e.g. tebentafusp); * Disunion requiring treatment * Patients treated for hematological cancer; * Persons deprived of their liberty or under guardianship (including curatorship); * Adults under court protection; * Inability to participate in the study for geographical, social or psychological reasons. * No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.). * Opposition to data use
References
Publications (0)
Data not yet available
No reference posted for this study.